ATOSSA THERAPEUTICS, INC. 8-K

What Happened

• On May 8, 2026, Atossa Therapeutics, Inc. (ATOS) announced its financial results for the quarter ended March 31, 2026 and provided a company update via a press release. The press release is attached to the Form 8-K as Exhibit 99.1.
• The filing states this information is furnished (not “filed”) under the securities laws, so it is not subject to Section 18 liability or certain disclosure liabilities under the Securities Act.

Key Details

• Event date: May 8, 2026.
• Reporting period: Quarter ended March 31, 2026.
• Disclosure format: Press release attached as Exhibit 99.1 to the Form 8-K.
• Legal note: Information in Items 2.02 and 9.01 (and Exhibit 99.1) is furnished, not filed, and will not be incorporated by reference into other SEC filings.

Why It Matters

• The company’s quarterly results and corporate update can affect investor assessment of Atossa’s recent performance and near-term prospects—key info for decisions about earnings, revenue trends, or clinical/program milestones.
• Because the press release is furnished rather than filed, investors should read the attached release directly for the detailed numbers and narrative, while noting the company’s limited legal exposure for these disclosures.